Bausch + Lomb: 3 Key Takeaways for Long-Term Investors
Premium product adoption is lifting margins faster than revenue growth, a sign of pricing power in a competitive market.
Bausch + Lomb reported robust third-quarter 2026 earnings, marking a 8% increase in revenue to $1.375 billion on a constant-currency basis. Earnings before interest, taxes, depreciation, and amortization (EBITDA) expanded, indicating strong core operating profitability driven by higher-margin product sales outpacing operating expenses. Additionally, operating cash flow reached $233 million, allowing the company to reduce its debt and net leverage ratio.
Premium intraocular lenses (IOLs) and prescription dry eye therapies were key drivers of revenue growth, with sales of premium IOLs surging 70% quarter-over-quarter. This surge contributed to heightened product mix and profit margins across all three operating segments: pharmaceuticals, surgical, and vision care.
Management highlighted the company's ongoing momentum, noting that full-year revenue and profit targets are rising. The strategic focus remains on maintaining a competitive edge through targeted investments in next-generation lens technology and prioritizing innovation to sustain long-term growth.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
